Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.

NCT07465718 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Wilson's Disease

Interventions

DRUG: TETA 4HCl formulation
DRUG: D-Penicillamine

Sponsor

Orphalan